Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16580016 | 0.88 | TSHR (0.58) | TSHRCYP3A4CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL12605245 | 0.86 | TSHR (0.60) | TSHRCYP3A4CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL1509491 | 0.86 | TSHR (0.96) | TSHRCYP3A4CYP2D6CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL9689647 | 0.84 | TSHR (1.00) | TSHRCYP3A4CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL15221484 | 0.84 | TSHR (0.61) | TSHRCYP3A4CYP2D6KDM4EGAA | |
| SCHEMBL9851585 | 0.83 | TSHR (0.53) | TSHRCYP3A4CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL12605246 | 0.83 | TSHR (0.77) | TSHRCYP3A4CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL19122470 | 0.81 | TSHR (0.59) | TSHRCYP2D6KDM4EGAA | |
| SCHEMBL10101694 | 0.81 | — | — | |
| SCHEMBL22359000 | 0.81 | TSHR (0.59) | TSHRKDM1AMAOBRCOR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| EP-3788041-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-03-10 | — | — | EP | disclosed |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-22 | — | — | US | disclosed |
| US-10723719-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2019-09-19 | — | — | US | disclosed |
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| WO-2016015605-A1 | COMPOUNDS AS CDK SMALL-MOLECULE INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-04 | — | — | WO | disclosed |
| US-8410112-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| EP-0417631-A2 | Condensed diazepinones, process for their preparation, and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | TSHR 3920/4885CYP3A4 3509/4885CYP2D6 3305/4885 |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | TSHR 3819/4885CYP3A4 4084/4885CYP2D6 3889/4885 |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | TSHR 4204/4885CYP3A4 2601/4885CYP2D6 2395/4885 |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | TSHR 3100/4885CYP3A4 4540/4885CYP2D6 4179/4885 |
| US-10723719-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | TSHR 857/4885CYP3A4 2435/4885CYP2D6 3454/4885 |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | TSHR 857/4885CYP3A4 2435/4885CYP2D6 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.